A novel tumor-specific gene therapy for bladder cancer

Medical Hypotheses

Volumn 53, Issue 2, 1999, Pages 130-135

  Pan, C X ^a   Koeneman, K S ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; RNA DIRECTED DNA POLYMERASE; TELOMERASE; VIRUS VECTOR;

BLADDER CANCER; ENZYME ACTIVITY; GENE THERAPY; HUMAN; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; TARGET CELL; TRANSITIONAL CELL CARCINOMA; TUMOR CELL;

EID: 0032854027     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1054/mehy.1998.0731     Document Type: Article

References (39)

1. Nakamura T. M., Morin G. B., Chapma K. B. Telomerase catalytic subunit homologs from fission yeast and human. Science. 277:1997;955-959.
2. Meyerson M., Counter C. M., Eaton E. N. hEST2 the putative human telomerase catalytic subunit gene is up-regulated in tumor cells and during immortalization. Cell. 90:1997;785-795.
3. Abremski K., Wierzbicki A., Frommer B., Hoess R. H. Bacteriophage P1 Cre-lox*p site specific recombination. Site-specific DNA topoisomerase activity of the Cre recombination protein. J Biol Chem. 261:1986;391-396.
4. Sternberg N., Sauer B., Hoess R., Abremski K. Bacteriophage P1 cre gene and its regulatory region. Evidence for multiple promoters and for regulation by DNA methylation. J Mol Biol. 187:1986;197-212.
5. Sauer B., Henderson N. Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1. Proc Natl Acad Sci USA. 85:1988;5166-5170.
6. Sauer B., Henderson N. Cre-stimulated recombination at loxP-containing DNA sequences placed into the mammalian genome. Nucleic Acids Res. 17:1989;147-161.
7. Gu H., Marth J. D., Orban P. C., Mossmann H., Rajewsky K. Deletion of a DNA polymerase β gene segment in T cells using cell type-specific gene targeting. Science. 265:1994;103-106.
8. Morin G. B. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesize TTAGGG repeats. Cell. 59:1989;521-529.
9. Counter C. M., Hirte H. W., Bacchetti S., Harley C. B. Telomerase activity in human ovarian carcinoma. Proc Natl Acad Sci USA. 91:1994;2900-2904.
10. Kim N. W., Piatyszek M. A., Prowse K. R. Specific association of human telomerase activity with immortal cells and cancer. Science. 266:1994;2011-2015.
11. Kim N. W. Clinical implications of telomerase in cancer. Eur J Cancer. 33:1997;781-786.
12. Harrington L., McPhail T., Mar V. A mammalian telomerase-associated protein. Science. 275:1997;973-977.
13. Feng J., Funk W. D., Wang S. S. The RNA component of human telomerase. Science. 269:1995;1236-1241.
14. Boring C. C., Squires T. S., Tong T. Cancer Statistics - 1995. Cancer J Clin. 45:1995;2.
15. Messing, E. M. Catalona, W. Urothelial Tumors of the Urinary Tract, Walsh, P. C.Retic, A. B.Vaughan, E. D.Wein, A. J. Campbell's Urology, 7th edn, W.B. Saunders, Philadelphia, 1998, 77, 2329.
16. Prout G. R., Barton B. A., Griffin P. P., Friedell G. Treated history of noninvasive grade 1 transitional cell carcinoma. J Urol. 148:1992;1413.
17. Spruck C. H. III, Ohneseit P. F., Gonzales-Zulueta M. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res. 54:1994;784.
18. Orlow I., Lacombe L., Hannon G. J. Deletion of the p16 and p15 genes in human bladder cancer. J Natl Cancer Inst. 20:1995;1499.
19. Williamson M., Elder P. A., Shaw M. E., Knowles M. A. P16 is a major deletion target at 9p21 in bladder cancer. Hum Mol Genet. 4:1995;1569.
20. Gruis N. A., Weaver-Feldhaus J., Liu Q. Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Am J Pathol. 146:1995;1199.
21. Esrig D., Elmajian D., Groshen S. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med. 331:1994;1259.
22. Esrig D., Spruck C. H., Nichols P. W. P53 nucleoprotein expression correlates with mutations in the p53 gene tumor grade and stage in bladder cancer. J Pathol. 143:1993;1390.
23. Harris C. C., Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med. 329:1993;1318.
24. Prout G. R., Koontz W. W., Coombs J. Long term fate of 90 patients with superficial bladder cancer randomly assigned to receive of not to receive therapy. J Urol. 130:1983;677-680.
25. Cookson M. S., Herr H. W., Zhang Z. The treated natural history of high risk superficial bladder cancer: 15 year outcome. J Urol. 158:1997;62-67.
26. Krane R. J., Siroky M. B., Fitzpatrick J. M. Clinical Urology. 1994;J. B. Lippincott, Philadelphia. p. 637-644.
27. Reznikoff C. A., Belair C. D., Yeager T. R. A molecular genetic model of human bladder cancer pathogenesis. Sem Oncol. 1996;571-584.
28. Harris B. C., Lune D. P. The dominating effect of mutant p53. Nat Genet. 9:1995;221-223.
29. Metcalfe A. M., Dixon R. M., Radda G. K. Wild-type but not mutant p53 activates the hepatocyte growth factor/scatter factor promoter. Nucl Acids Res. 25:1997;983-986.
30. Finer M. H., Dull T. J., Qin L., Farson D., Roberts M. R. Kat: a high-efficiency retroviral transduction system for primary human T lymphocytes. Blood. 83:1994;43-50.
31. Soneoka Y., Cannon P. M., Ramsdale E. E. A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucl Acids Res. 23:1995;628-633.
32. Hofmann A., Nolan G. P., Blau H. M. Rapid retroviral delivery of tetracycline-inducible genes in a single autoregulatory cassette. Proc Natl Acad Sci USA. 93:1996;5185-5190.
33. Paulus W., Baur I., Boyce F. M., Breakefield X. O., Reeves S. A. Self-containing, tetracycline-regulated retroviral vector system for gene delivery to mammalian cells. J Virol. 70:1996;62-67.
34. Broccoli D., Young J. W., de Lange T. Telomerase activity in normal and malignant hematopoietic cells. Proct Natl Acad Sci USA. 92:1995;9082-9086.
35. Hiyama K., Hirai Y., Kyoizumi S. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J Immunol. 155:1995;3711-3715.
36. Pan C., Xue B. H., Ellis T. M., Peace D. J., Diaz M. O. Changes in telomerase activity and telomere length during human T lymphocyte senescence. Exp Cell Res. 231:1997;346-353.
37. Hiyama E., Hiyama K., Yokoyama T., Matsuura Y., Piatyszek M. A., Shay J. W. Correlating telomerase activity levels with human neuroblastoma outcomes. Nat Med. 1:1995;249-255.
38. Yu S.-F., von Rueden T., Kantoff P. W. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci USA. 83:1986;3194-3198.
39. Sharp J. G., Bishop M., Chan W. C. Detection of minimal residual disease in hematopoietic tissues. Ann NY Acad Sci. 770:1995;242-261.